What is Bioject Medical Technologies Total Inventories?
Bioject Medical Technologies's total inventories for the quarter that ended in Sep. 2011 was $0.89 Mil. Bioject Medical Technologies's average total inventories from the quarter that ended in Jun. 2011 to the quarter that ended in Sep. 2011 was $1.20 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Bioject Medical Technologies's Net-Net Working Capital per share for the quarter that ended in Sep. 2011 was $-0.58.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Bioject Medical Technologies's Days Inventory for the
three
months ended in Sep. 2011 was 58.95.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Bioject Medical Technologies's Inventory Turnover for the quarter that ended in Sep. 2011 was 1.55.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Bioject Medical Technologies's Inventory-to-Revenue for the quarter that ended in Sep. 2011 was 0.38.
Bioject Medical Technologies Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Bioject Medical Technologies Total Inventories Chart
Bioject Medical Technologies Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Bioject Medical Technologies (OTCPK:BJCT) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Bioject Medical Technologies's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2011 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Bioject Medical Technologies's Inventory to Revenue for the quarter that ended in Sep. 2011 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Bioject Medical Technologies Total Inventories Related Terms
Thank you for viewing the detailed overview of Bioject Medical Technologies's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Bioject Medical Technologies (Bioject Medical Technologies) Business Description
Bioject Medical Technologies Inc commenced operations in 1985 and is a developer and manufacturer of needle-free injection therapy systems (NFITS). The Companys long-term goal is to become supplier of needle-free injection systems to the pharmaceutical and biotechnology industries. It focused its business development efforts on new and existing licensing and supply agreements with pharmaceutical and biotechnology companies, as well as numerous research agreements that could guide to long-term agreements. The Companys pipeline of prospective new partnerships remains active. It is also actively pursuing additional opportunities both domestically and overseas as it expands its current product line. The Companys Biojector 2000 system (B2000) consists of two components: a hand-held, reusable jet injector and a sterile, single-use, disposable plastic syringe capable of delivering variable doses of medication up to 1.0 mL. Drug Reconstitution System - The needle-free drug reconstitution system allows for the transfer of diluents to reconstitute powdered medications into liquid form and withdrawal of liquid medication into a syringe without the use of a needle. Vitajet - The Vitajet is also composed of two components, a portable injector unit and a disposable syringe. It is smaller and lower in cost than other products in its needle-free offering. ZetaJet - The ZetaJet is Biojects latest advance in needle-free delivery systems. It consists of two components, the portable injector and an auto-disabling disposable syringe. The medical equipment market is very competitive. Bioject Medical Technologies has two patents: Biojector 2000 and Vitajet. The Companys products and manufacturing operations are subject to extensive government regulations, both in the U.S. and abroad. In the U.S., the Food and Drug Administration (FDA) administers the Federal Food, Drug and Cosmetic Act (FFDCA) and has adopted regulations to administer the FFDCA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BJCT has been successfully added to your 